New Street set a price target of $12 for NASDAQ:AQST, indicating a potential upside of approximately 193%. The FDA's Complete Response Letter (CRL) for Anaphylm has caused a temporary setback, but AQST's stock has still increased by 38.98%. AQST's market capitalization stands at approximately $500.21 million, with a significant trading volume on the NASDAQ exchange.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a pharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs. The company specializes in oral film-based drug delivery systems. AQST's competitors include companies like Teva Pharmaceuticals and Viatris (formerly Mylan), which also focus on drug delivery technologies.
On February 2, 2026, New Street set a price target of $12 for AQST, while the stock was trading at $4.10. This target suggests a potential upside of approximately 193%. Despite the recent setback with the FDA's Complete Response Letter (CRL) for Anaphylm, AQST's stock has seen a significant increase of 38.98%, rising by $1.15.
The FDA's CRL for Anaphylm, a treatment for Type I allergic reactions, highlighted deficiencies in the human factors validation study. This has temporarily halted discussions on labeling and post-marketing commitments. However, Daniel Barber, President and CEO of AQST, remains optimistic, focusing on addressing these human factors issues. AQST's stock has shown volatility, with a daily range between $3.79 and $4.39. Over the past year, the stock has fluctuated between a high of $7.55 and a low of $2.12. The company's market capitalization is approximately $500.21 million, with a trading volume of 60.81 million shares on the NASDAQ exchange.
Despite the FDA's decision not to approve Anaphylm, AQST is actively discussing next steps to address the concerns and advance the product's development. The outcome of these efforts is crucial for the company's future, as Anaphylm represents a significant opportunity in the treatment of anaphylaxis.
